Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma
Xinqi Wu(Dana-Farber Brigham Cancer Center), F. Stephen Hodi(Harvard University), Mariano Severgnini(Dana-Farber Cancer Institute), Anita Giobbie‐Hurder(Institute for Tourism), Scott J. Rodig(Brigham and Women's Hospital), Erin M. Connolly(Dana-Farber Cancer Institute), Jingjing Li(Weifang Medical University), Xiaoyun Liao(Bristol-Myers Squibb (Germany)), Jun Zhou(Brigham and Women's Hospital)
Cited by 40
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k